Figure 5.

The effects of confounding factors on CB1R immunoreactivity levels in schizophrenia. Mean (bar) and individual subject (circles) ROD levels of CB1R immunoreactivity in the subjects with schizophrenia grouped by potential confounding factors. Neither sex, diagnosis of schizoaffective disorder, suicide, antidepressant medication use at the time of death, benzodiazepine use at the time of death, antipsychotic medication use at the time of death, diagnosis of substance abuse/dependence at the time of death, nor history of cannabis use/abuse significantly affected levels of CB1R immunoreactivity. Numbers in bars indicate the number of subjects with schizophrenia in each category. A history of cannabis use was unknown for five of the schizophrenia subjects in cohort 2; thus those subjects were not included in the analysis.